GeneOne Life science made application of COVID-19 vaccine composition patent

CEO Park Young-keun of GeneOne Life science [Photo provided = GeneOne Life science]

On 22nd of this month GeneOne Life science announced that they made application of patent of phase 1/2a clinical trial undergoing composition including COVID-19 vaccine (GLS-5310).

The company said that the invention is named Vaccine Composition for the Prevention of SARS-CoV-2 which added ORF3a protein in addition to spike protein to improve wide vaccine immune reaction and prevention capability. Also they used the bicistronic strategy by fitting 2 antigen in 1 plasmid to realize fast and efficient vaccine production

CEO Park said that they utilized the outcome vaccine platform that was supported by a national project to develop the research and finally make application. He added that the COVID-19 vaccine sovereignty may be secured by the application.

Website: : http://cms.wip-news.com/news/articleView.html?idxno=7932